Carrie Jones

The National Institute of Mental Health has awarded a $3.4 million grant to professor Thilo Womelsdorf to study the underlying mechanisms of action for potential drugs to regulate cognitive function and brain network activity affected in schizophrenia without debilitating side effects. Read More

Prothena and the Warren Center for Neuroscience Drug Discovery have entered into a collaborative research agreement to develop new small molecule therapeutics for the treatment of Alzheimer’s disease in individuals with Down syndrome. Read More

Vanderbilt University has signed an exclusive worldwide license and research collaboration agreement with Neumora Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience. Read More

VU319, an investigational drug product developed by Vanderbilt researchers, targets one of medicine’s most bedeviling challenges: improving memory loss in people with Alzheimer’s disease. Read More

Ten outstanding faculty members from across the university have been selected for the 2020 cohort of Chancellor Faculty Fellows. This group is composed of highly accomplished, recently tenured faculty from a wide variety of disciplines and areas of expertise. Read More

Vanderbilt University’s Warren Center for Neuroscience Drug Discovery has entered into an exclusive worldwide licensing and collaboration agreement with San Diego-based ACADIA Pharmaceuticals Inc. to develop treatments for disorders like Alzheimer’s and schizophrenia. Read More

Ancora Innovation, LLC, the new collaboration between Vanderbilt and Deerfield Management established earlier this year, has completed its inaugural proposal review process and announced two projects selected for funding. Read More

Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects. Read More

A new compound developed at Vanderbilt treats multiple symptoms of schizophrenia in an animal model, without causing sedation. Read More

Drug-like molecules described by Vanderbilt researchers could lead to Parkinson's treatments with fewer side effects. Read More

The discovery of new compounds that work in a fundamentally different way than those in existing schizophrenia medications may allow for more normal function of brain cells involved in schizophrenia. Read More

Researchers at Vanderbilt University Medical Center, in collaboration with Seaside Therapeutics in Cambridge, Mass., have achieved a milestone in the development of a potential new treatment for fragile X syndrome, the most common genetic cause of autism. Read More

Vanderbilt University Medical Center has established a new Center for Neuroscience Drug Discovery to accelerate research that may lead to new treatments for Parkinson's disease, schizophrenia and other disorders of the brain. Read More

Watch video of Dr. Paul W. Ragan, associate professor of psychiatry, and Carrie Jones, assistant professor of pharmacology, speaking March 3. Post Traumatic Stress Disorder, or PTSD, is a severe anxiety disorder that occurs in people who have experienced physical or psychological trauma. Triggering events can include experiences like military combat, car accidents,… Read More

"Brainstorm 2011," a series of free public events about brain research hosted by Vanderbilt University, will explore post-traumatic stress disorder, depression and the mysteries of feelings and perception throughout the month of March. Read More